Increased cortical kynurenate content in schizophrenia (Q43766055)

26 November 2017

title

Increased cortical kynurenate content in schizophrenia (English)

1 reference

26 November 2017

0 references

4

Medoff D

1 reference

26 November 2017

5

Tamminga CA

1 reference

26 November 2017

Schwarcz R

1

1 reference

26 November 2017

Rassoulpour A

series ordinal

2

1 reference

26 November 2017

Wu HQ

series ordinal

3

1 reference

26 November 2017

Roberts RC

series ordinal

6

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

26 November 2017

published in

Biological Psychiatry

1 reference

26 November 2017

volume

50

1 reference

26 November 2017

issue

7

1 reference

26 November 2017

page(s)

521-530

1 reference

Schizophrenia, sensory gating, and nicotinic receptors

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Schizophrenia: a subcortical neurotransmitter imbalance syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Comparison of the Neurochemical and Behavioral Effects Resulting from the Inhibition of Kynurenine Hydroxylase and/or Kynureninase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Is there a viral or immune dysfunction etiology to schizophrenia? Re-evaluation a decade later

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: a reverse transcriptase-polymerase chain reaction (RT-PCR) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Tryptophan loading: consequent effects on the synthesis of kynurenine and 5-hydroxyindoles in rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

The dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Glutamate in schizophrenia: clinical and research implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Metabolism of [5‐3H]Kynurenine in the Rat Brain In Vivo: Evidence for the Existence of a Functional Kynurenine Pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Quantification of 3-hydroxykynurenine in brain by high-performance liquid chromatography and electrochemical detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

2-Oxoacids regulate kynurenic acid production in the rat brain: studies in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Determination of serum kynurenine and hepatic tryptophan dioxygenase activity by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: I. Comparisons with healthy control subjects and neuroleptic-treated/unmedicated pairs analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: II. Correlations with psychopathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Intravenous administration of L-kynurenine to rhesus monkeys: effect on quinolinate and kynurenate levels in serum and cerebrospinal fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Brain tryptophan metabolism in schizophrenia: A post mortem study of metabolites on the serotonin and kynurenine pathways in schizophrenic and control subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Effects of optical isomers of ketamine on excitation of cat and rat spinal neurones by amino acids and acetylcholine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Presence of Kynurenic Acid in the Mammalian Brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Clinical experience with excitatory amino acid antagonist drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Two kynurenine aminotransferases in human brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Glutamate receptor dysfunction and schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Dopaminergic control of kynurenate levels and N-methyl-D-aspartate toxicity in the developing rat striatum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Abnormal excitatory neurotransmitter metabolism in schizophrenic brains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

D-serine added to antipsychotics for the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Identification and quantification of kynurenic acid in human brain tissue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

On the disposition of intrahippocampally injected kynurenic acid in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Kynurenic Acid in the Quinolinate-lesioned Rat Hippocampus: Studies In Vitro and In Vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

Quinolinic acid in neurological disease: opportunities for novel drug discovery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Schizophrenia and glutamatergic transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901078-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(01)01078-2

1 reference

26 November 2017

1 reference